Form 4: Aligos Therapeutics CFO Acquires Stock Options

Lesley Ann Calhoun, CFO of Aligos Therapeutics, reports the acquisition of stock options.

Summary

• Lesley Ann Calhoun, the Chief Financial Officer of Aligos Therapeutics, Inc. (ALGS), filed a Form 4 on March 4, 2024, reporting a transaction.
• On March 1, 2024, Calhoun acquired stock options to purchase 308,940 shares of Aligos Therapeutics common stock at an exercise price of $1.13.
• The options vest in 48 equal monthly installments starting March 1, 2024, and will be fully vested on the fourth anniversary of the Vesting Commencement Date, contingent upon continued service.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard executive compensation practice. The grant itself doesn't indicate overwhelmingly positive or negative news.

Positives

• The acquisition of stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The vesting schedule of 48 months is a typical vesting period for stock options.
• Comparing the size of the grant to similar companies and executive roles would provide further context.

Stakeholder Impact

• The stock option grant could incentivize the CFO to improve company performance, potentially benefiting shareholders.
• The grant has a minimal immediate impact on other stakeholders.

Key Dates